Early diagnosis of drug-resistant tuberculosis is critical in order to establish appropriate drug treatment regimens and to prevent the further transmission of resistant strains. Line probe assays (LPAs) are promising rapid diagnostics for use in low income settings, and can be used to screen smear-positive sputum samples for resistance to rifampicin (RIF) and isoniazid (INH) in as little as 1–2 days. Though the diagnostic performance of these assays has been well evaluated, little research has elucidated the true nature of indeterminate LPA results, or assessed the ability of these assays to perform on a wide range of clinical samples
We evaluated the performance of the commercially available Genotype MTBDRplus LPA against conventional MGIT 960 culture and drug susceptibility testing (DST) results for 308 pulmonary (PTB) and 32 extrapulmonary (EPTB) tuberculosis samples. Invalid LPA results (defined as missing the MTB identification band) were obtained for 18 PTB samples, which were excluded from further analysis. The sensitivity and specificity of the Genotype MTBDRplus assay for multidrug-resistant tuberculosis (MDR-TB), based upon the results obtained for the remaining 322 samples, was 95.2% and 95.1%, respectively. 13.7% (40/290) of the PTB samples were not interpretable, or indeterminate, by LPA (defined as having the absence of both wild type and corresponding mutation bands) for INH and/or RIF and were further evaluated by pyrosequencing (PSQ). Contrary to standard LPA interpretation, INH and RIF susceptibility were confirmed by both DST and PSQ in 7.5% (3/40) and 27.5% (11/40) of indeterminate samples, respectively. When LPA test results were not interpretable in this study, PSQ was found to be a valuable and rapid technique to resolve discrepancies.